DexCom Stock Price and Value Analysis

DexCom (NasdaqGS:DXCM) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold DexCom to reach your target.

Target type

DXCM Free Cash Flow Trend

Free Cash Flow trendline for DXCM
Free Cash Flow trendline for DexCom
CSV

Based on historical returns, we believe that DexCom can grow its free cash at a rate of about 1%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company is solid.
  • This stock looks overpriced.
  • This company is making money at a modest rate.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the DXCM Numbers

DXCM Price
(DexCom stock price per share)
$79.32
[?] DXCM Fair Price
(based on intrinsic value)
$8.23
[?] DXCM Safety Price (based on a variable margin of safety) $5.35
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 54% higher than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Medical Devices stocks
[?] Cash Yield 0.09%
[?] Free Cash Flow Jitter 72%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 15,933,006 shares shorted. With 371,608,299 shares available for purchase and an average trading volume over the past 10 trading days of 3,914,020, it would take at least 4.1 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2009 1093557 -42.4
2010 1093557 -47.6
2011 1093557 -36.1
2012 1093557 -39.9
2013 1093557 -4.7
2014 1093557 13.9
2015 1093557 34
2016 1093557 31.7
2017 1093557 56.2
2018 1093557 75.5
2019 1093557 234
2020 1093557 362
2021 1093557 262
2022 1093557 429
2023 1093557 475
2024 1093557 680
2025 1093557 1,098

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 7 fiscal years from 2009 to 2025 with positive net income, operating cash flow totaled $5,081 million against net income of $3,163 million, or 1.61 times. Net income was negative in 10 of the 17 years, and those years are left out of the ratio.

In 2025, capital expenditures were $364 million, 25.2% of operating cash flow of $1,441 million, which leaves an estimated $1,077 million after capex. Across the 13 years with reported capex, it averaged 43.1% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2009 -53.5 -39.4 3 n/a
2010 -55.2 -42.7 6.9 n/a
2011 -44.7 -30.1 8 n/a
2012 -54.5 -33.1 9.5 n/a
2013 -29.8 2.4 7.9 n/a
2014 -22.4 23.6 16.2 n/a
2015 -57.6 49 33.3 n/a
2016 -65.6 56.2 55.7 n/a
2017 -50.2 92 66 n/a
2018 -127 123 67.1 n/a
2019 101 315 180 3.11
2020 550 476 199 0.87
2021 217 443 389 2.04
2022 341 670 365 1.96
2023 542 749 237 1.38
2024 576 990 359 1.72
2025 836 1,441 364 1.72

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 5 fiscal years from 2018 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $2,758 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In 5 of the 5 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $2,596 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, cash spent repurchasing shares was $500 million, 45.5% of estimated free cash flow of $1,098 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2018 75.5 n/a 100 100 132.4%
2022 429 n/a 558 558 129.9%
2023 475 n/a 689 689 145.1%
2024 680 n/a 750 750 110.3%
2025 1,098 n/a 500 500 45.5%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $29.7 million in 2009 and $4,662 million in 2025, a compound annual growth rate of 37.2% over 16 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.

Revenue rose 15.6% from 2024 to 2025.

Our estimated free cash flow was $1,098 million in 2025, 23.6% of revenue. In 2009 the estimated margin was negative 142.7%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2009 29.7 -42.4 -142.7%
2010 48.6 -47.6 -98.0%
2011 76.3 -36.1 -47.3%
2012 99.9 -39.9 -40.0%
2013 160 -4.7 -2.9%
2014 259 13.9 5.4%
2015 402 34 8.5%
2016 573 31.7 5.5%
2017 719 56.2 7.8%
2018 1,032 75.5 7.3%
2019 1,476 234 15.9%
2020 1,927 362 18.8%
2021 2,449 262 10.7%
2022 2,910 429 14.8%
2023 3,622 475 13.1%
2024 4,033 680 16.9%
2025 4,662 1,098 23.6%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $918 million against total liabilities of $3,594 million, or 25.5% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 56.7% of total assets in 2025, compared with 20.9% in 2010, an increase of 35.7 percentage points.

Stockholders equity was $2,746 million in 2025, compared with $61 million in 2010, a rise of 4401.6%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 33.5% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2010 77.2 4.9 16.2 61
2011 121 2.6 16 105
2012 106 8.1 29 77
2013 123 43.2 38.4 84.1
2014 185 71.8 44.4 140
2015 292 86.1 70.8 221
2016 403 94.5 119 284
2017 904 442 485 419
2018 1,916 1,137 1,253 663
2019 2,395 446 1,512 883
2020 4,291 818 2,464 1,552
2021 4,933 1,053 2,891 2,042
2022 5,392 642 3,260 2,132
2023 6,265 566 4,196 2,069
2024 6,485 606 4,382 2,103
2025 6,340 918 3,594 2,746

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $79.32, the price is above what our model can produce for average free cash flow growth between -30 and 60 percent a year, so no implied growth rate is shown. Our model assumes 1.2 percent a year for this stock. This is not a forecast of growth or a price target.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $26.5 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $63.46 above range
Current price $79.32 above range
20 percent above the current price $95.18 above range
Our model (stored fair price) $8.23 1.2%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Only 12 of the 17 fiscal years under DexCom's current filer show positive free cash flow.

At $79.32, the price is above our fair value estimate of $8.23 for DexCom.

Free cash flow is volatile from year to year, with a variability measure of 72%.

Dividends are not in our data for DexCom.

Our value investing guide explains how to test these numbers against the filings themselves.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 54% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 100% below the average for stocks in the Medical Devices industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Devices industry, the ones closest in market capitalization to DexCom, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
DexCom (DXCM) 29,582 31.2 - 0.1% 864% above
West Pharmaceutical Services (WST) 27,189 43.8 0.2% 0.6% 320% above
ResMed (RMD) 33,143 21.5 1.0% 1.2% 81% above
Baxter International (BAX) 13,135 - 0.2% 11.4% 61% below
Penumbra (PEN) 12,578 80.4 - - 781% above
Globus Medical (GMED) 8,861 16.5 - - 61% above
Teleflex Incorporated (TFX) 6,408 79.6 0.8% 5.7% 24% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1093557.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 5 of the 17 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-21
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: DXCM annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in DXCM

Does DexCom have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: DXCM

This example shows how we apply the Trendshare checklist to DXCM: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 79.32
    • Market cap: $30B
    • EPS: 2.54
  2. Step 2 — Valuation checks

    • P/E: 31.228
    • FCF yield: 0.1%
    • Date checked: Nov 21, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.